| BIOGEN INC. DL -,0005 | 209.250 / -0.12% |
| Date/Time | 08/22 / 16:09 |
| Chg. / Chg.(%) | -0.250 / -0.12% |
| Bid | 209.250 |
| Ask | 209.500 |
| Open | 209.500 |
| Previous Close | 209.500 |
| High | 210.700 |
| Low | 209.050 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 4161 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Lang & Schwarz |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 231.8500 |  |
66,040 |
| Cboe US | 232.44 | |
4,615 |
| IEX | 231.16 | |
2,475 |
| Vienna Globa.. | 209.61 | |
48 |
| TradeGate | 209.450 | |
20 |
| Frankfurt | 209.4000 | |
10 |
| München | 209.40 | |
1 |
| Hamburg | 209.40 | |
0 |
| Düsseldorf | 209.40 | |
0 |
| Berlin | 209.55 | |
0 |
| Hannover | 209.40 | |
0 |
| Lang & Schwa.. | 209.250 | |
|
| gettex | 210.250 | |
|
| Stuttgart | 209.450 | |
|
| Xetra | 209.95 | 65 | |
| London Inter.. | 232.65 | 9 | |
| SIX Swiss Ex.. | 232.00 | ||
| Mexico | 4,569.20 | 200 |
News
- Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
08/20/2019 / 13:30 - GlobeNewswire - Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
07/30/2019 / 13:30 - GlobeNewswire - Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors
07/25/2019 / 14:30 - GlobeNewswire - Biogen's GAAP diluted EPS in Q2 increases 88% YoY
07/23/2019 / 12:35 - TeleTrader - Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
07/01/2019 / 13:30 - GlobeNewswire
Real-time